BRPI0508134A - sistema transportador, uso do sistema transportador e método para a produção de um sistema transportador - Google Patents
sistema transportador, uso do sistema transportador e método para a produção de um sistema transportadorInfo
- Publication number
- BRPI0508134A BRPI0508134A BRPI0508134-3A BRPI0508134A BRPI0508134A BR PI0508134 A BRPI0508134 A BR PI0508134A BR PI0508134 A BRPI0508134 A BR PI0508134A BR PI0508134 A BRPI0508134 A BR PI0508134A
- Authority
- BR
- Brazil
- Prior art keywords
- conveyor system
- producing
- carrying system
- structures
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SISTEMA TRANSPORTADOR, USO DO SISTEMA TRANSPORTADOR E MéTODO PARA A PRODUçãO DE UM SISTEMA TRANSPORTADOR A presente invenção refere-se a um sistema transportador na forma de nano partículas com base em proteína para um enriquecimento específico de células, intracelular, de pelo menos uma substância farmacologicamente ativa, o qual tem estruturas que são acopladas por meio de grupos reativos, as referidas estruturas permitindo uma fixação específica de célula e uma absorção celular das nano partículas; e um método para a produção do referido sistema.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004011776A DE102004011776A1 (de) | 2004-03-09 | 2004-03-09 | Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen |
PCT/EP2005/002185 WO2005089797A2 (de) | 2004-03-09 | 2005-03-02 | Trägersystem in form von nanopartikeln auf proteinbasis zur zellspezifischen anreicherung von pharmazeutisch aktiven wirtstoffen |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508134A true BRPI0508134A (pt) | 2007-07-17 |
Family
ID=34994419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508134-3A BRPI0508134A (pt) | 2004-03-09 | 2005-03-02 | sistema transportador, uso do sistema transportador e método para a produção de um sistema transportador |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080095857A1 (pt) |
EP (1) | EP1722816A2 (pt) |
JP (1) | JP2007527881A (pt) |
KR (1) | KR20070006828A (pt) |
CN (1) | CN1993145A (pt) |
AU (1) | AU2005223986B2 (pt) |
BR (1) | BRPI0508134A (pt) |
CA (1) | CA2558730A1 (pt) |
DE (1) | DE102004011776A1 (pt) |
IL (1) | IL177879A0 (pt) |
NZ (1) | NZ549355A (pt) |
RU (1) | RU2388463C2 (pt) |
WO (1) | WO2005089797A2 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
DE102006011507A1 (de) | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
JP2008162981A (ja) * | 2006-12-28 | 2008-07-17 | Japan Science & Technology Agency | ビオチン化ないしホーミングペプチド提示型バイオナノカプセル |
GB0724360D0 (en) * | 2007-12-14 | 2008-01-23 | Glaxosmithkline Biolog Sa | Method for preparing protein conjugates |
US9125949B2 (en) * | 2008-12-30 | 2015-09-08 | University Of North Texas | Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials |
US9211283B2 (en) * | 2009-12-11 | 2015-12-15 | Biolitec Pharma Marketing Ltd | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
RU2542417C2 (ru) * | 2013-05-17 | 2015-02-20 | Александр Александрович Кролевец | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов |
RU2576239C2 (ru) * | 2014-03-26 | 2016-02-27 | Александр Александрович Кролевец | Способ получения нанокапсул антисептика-стимулятора дорогова (асд) 2 фракция |
EP3142647A4 (en) * | 2014-05-16 | 2017-12-20 | Dana-Farber Cancer Institute, Inc. | Protein-based particles for drug delivery |
WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
AR109685A1 (es) * | 2016-10-10 | 2019-01-09 | Abraxis Bioscience Llc | Composiciones de nanopartículas y métodos para fabricarlas y usarlas |
JPWO2020241562A1 (pt) * | 2019-05-24 | 2020-12-03 | ||
WO2021064678A1 (en) * | 2019-10-04 | 2021-04-08 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec - Associação | Hydrogel-like particles, methods ans uses thereof |
CN112451679A (zh) * | 2020-11-25 | 2021-03-09 | 天津医科大学第二医院 | 结合了纳米药物载体的卡介苗复合体及其制备方法 |
CN113588523B (zh) * | 2021-07-26 | 2022-03-29 | 浙江大学 | 一种用于质谱流式细胞技术的基于框架结构的纳米颗粒及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506436A (ja) * | 1997-06-13 | 2002-02-26 | ザ ジョンズ ホプキンス ユニバーシティー | 治療用ナノスフェア |
WO2001091808A2 (en) * | 2000-06-01 | 2001-12-06 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
DE10121982B4 (de) * | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
JP2004198915A (ja) * | 2002-12-20 | 2004-07-15 | Shin Etsu Chem Co Ltd | ポジ型レジスト組成物及びパターン形成方法 |
EP1598419A1 (en) * | 2003-02-28 | 2005-11-23 | Mitsubishi Pharma Corporation | Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent |
-
2004
- 2004-03-09 DE DE102004011776A patent/DE102004011776A1/de not_active Withdrawn
-
2005
- 2005-03-02 KR KR1020067020921A patent/KR20070006828A/ko not_active Application Discontinuation
- 2005-03-02 NZ NZ549355A patent/NZ549355A/en unknown
- 2005-03-02 CA CA002558730A patent/CA2558730A1/en not_active Abandoned
- 2005-03-02 JP JP2007502234A patent/JP2007527881A/ja not_active Ceased
- 2005-03-02 BR BRPI0508134-3A patent/BRPI0508134A/pt not_active IP Right Cessation
- 2005-03-02 AU AU2005223986A patent/AU2005223986B2/en not_active Ceased
- 2005-03-02 US US10/590,601 patent/US20080095857A1/en not_active Abandoned
- 2005-03-02 CN CNA2005800073779A patent/CN1993145A/zh active Pending
- 2005-03-02 EP EP05715659A patent/EP1722816A2/de not_active Withdrawn
- 2005-03-02 WO PCT/EP2005/002185 patent/WO2005089797A2/de active Application Filing
- 2005-03-02 RU RU2006130260/15A patent/RU2388463C2/ru not_active IP Right Cessation
-
2006
- 2006-09-04 IL IL177879A patent/IL177879A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005223986B2 (en) | 2010-12-23 |
WO2005089797A2 (de) | 2005-09-29 |
CN1993145A (zh) | 2007-07-04 |
KR20070006828A (ko) | 2007-01-11 |
AU2005223986A1 (en) | 2005-09-29 |
WO2005089797A3 (de) | 2006-11-23 |
EP1722816A2 (de) | 2006-11-22 |
DE102004011776A1 (de) | 2005-11-03 |
US20080095857A1 (en) | 2008-04-24 |
RU2388463C2 (ru) | 2010-05-10 |
RU2006130260A (ru) | 2008-02-27 |
IL177879A0 (en) | 2006-12-31 |
CA2558730A1 (en) | 2005-09-29 |
NZ549355A (en) | 2009-09-25 |
JP2007527881A (ja) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508134A (pt) | sistema transportador, uso do sistema transportador e método para a produção de um sistema transportador | |
BRPI0908686B8 (pt) | método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas | |
BRPI0511802A (pt) | processo para criação de meios para uso em separadores de ar/óleo | |
BRPI0616071B8 (pt) | métodos de revestir uma micropartícula cristalina pré-formada em suspensão com um agente ativo | |
BRPI0520279A2 (pt) | sistemas e mÉtodos para turbinas a vento acorrentadas | |
DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
ECSP10010688A (es) | Activadores de glucoquinasa | |
CL2008002873A1 (es) | Anticuerpo anti-glipican 3/gpc3; composicion que lo comprende; agente anti-canceroso que lo comprende; acido nucleico que codifica dicho anticuerpo; celula hospedera aislada que comprende dicho acido nucleico; metodo para la preparacion de dicho anticuerpo | |
BR112015025803A2 (pt) | método para tratar um substrato animal | |
GT200600112A (es) | Composiciiones de tigeciclina y metodos de preparacion | |
BRPI0413927B8 (pt) | composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição | |
BRPI0611872B8 (pt) | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica | |
BRPI0515684A (pt) | formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas | |
BRPI0514697A (pt) | método para selecionar um cardiomiócito usando mitocÈndrias intracelulares como um indicador | |
BR112013033388A2 (pt) | composição cimentícia e mistura | |
BRPI0602671A (pt) | processo para a preparação de terpolìmeros de nitrila de mooney baixa | |
CL2009001080A1 (es) | Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo. | |
BRPI0401103A (pt) | Composição compósita, método para formar a mesma, composição modificada, e, método para formar a mesma | |
BRPI0819922A8 (pt) | material sólido poroso, gerador de gás para gerar gás nitrogênio, e, processo para gerar gás nitrogênio | |
CO6170367A2 (es) | Una resina de intercambio ionico y un proceso para su uso | |
BRPI1010546B8 (pt) | processo para produzir composto, método para isolar e purificar cristais de solvato do composto, e, uso do composto | |
BR112012005995A2 (pt) | composição para uso como revestimento translúcido remoção de nox | |
PE20070529A1 (es) | Composicion farmaceutica que contiene azodicarbonamida micronizada y su preparacion | |
NO20060183L (no) | Papirfremstilling med modifiserte silikasoler som mikropartikler | |
BRPI0919422A2 (pt) | Uso de pelo menos um composto, processo para melhorar o desenvolvimento de gramineas, e, agente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 9/51 (2006.01), A61K 47/55 (2017.01), A61K 47 |